Site-Specific Drug Delivery

Programme 2014 - 2020 INTERREG V-A France - Belgium - The Netherlands - United Kingdom (Les Deux Mers / Two seas / Twee Zeeën)

Date of latest update: 2024-12-17

Description

Description (EN):

To develop innovative medical products allowing for site-specific drug distribution in the patient’s body to reduce undesired side effects and increase therapeutic efficacies. The drugs are to be released locally in the living organism at pre-programmed rates. This is to optimize the drug concentrations at their site of action, and to minimize their concentrations in the rest of the human body (where no drug is needed, causing only undesired side effects).

Achievements (EN):

The Site Drug project allowed fostering the European competitiveness in a crucial domain: "Drug Product Development". Ten highly complementary partners joined their forces and intensively collaborated across national borders, being based in France, Belgium, UK, and The Netherlands. Important, not only national, but also scientific borders were overcome between pharmaceutics, medicine, microbiology, engineering & physics. Novel drug products for better medical treatments with reduced undesired site effects were developed: these advanced medicines are able to optimise the drug concentration at the site of action in the patient’s body and to minimize the “drug waste” into the other parts of the organism (where the drug is not needed and causes damage). This is achieved by novel drug delivery systems, which locally release the drug at specific sites in the human body. Prototypes of these new drug products have been prepared and thoroughly characterized. Local and controlled drug delivery has been enabled to the inner ear to treat hearing loss, in the peritoneal cavity to treat metastases from ovarian cancer, in the colon to treat Crohn's disease, and to the tissue around the breast implants to minimize the risk of post-operative complications. Cutting-edge knowhow and equipment at the Universities of Cambridge, Delft, Ghent, Leiden, Lille & London and in pharmaceutical companies were used to characterise and optimise the novel technologies. Special emphasis was placed on the transferability of the innovations into clinical practice and new drug products on the market, paying great attention to the up scalability of the manufacturing procedures and intense collaboration with industrial partners. This highly interdisciplinary work became only possible due to the cross-border action supported by the Interreg 2 Seas Programme. The required knowledge & facilities, in fact, were not provided in a single Member State but through joint cooperation among organisations. Greater awareness was risen on this project in the scientific and medical community, specifically via online & onsite conferences with oral presentations & scientific discussions, journal articles, as well as dissemination campaigns reaching more than 10,000 scientists.

Website: https://www.site-drug.org/

Delivered Outputs (EN):

The main outputs of the Site Drug project are: - One advanced drug product for the treatment of Crohn’s disease and ulcerative colitis (TRL 5) - One intraperitoneal implant with controlled drug release for local cancer treatment (TRL 5) - One drug releasing implant for breast replacement upon resection due to cancer (TRL 5) - One inner ear implant for the local treatment of hearing loss/deafness (TRL 5) - A novel in vitro release test method simulating the conditions in the gastrointestinal tract of a patient (TRL 5) - A feasibility study demonstrating the validity of the newly developed prototypes Check the “Outputs” section below to download related material and see “Main Achievements” section for further information about the achieved results.

Thematic information

Health and social services

Specific Objective: Increase the delivery of innovation in smart specialisation sectors

Thematic Objective: (01) strengthening research, technological development and innovation by:

Investment Priority:

(01b) promoting business investment in R&I, developing links and synergies between enterprises, research and development centres and the higher education sector, in particular promoting investment in product and service development, technology transfer, social innovation, eco-innovation, public service applications, demand stimulation, networking, clusters and open innovation through smart specialisation, and supporting technological and applied research, pilot lines, early product validation actions, advanced manufacturing capabilities and first production, in particular in key enabling technologies and diffusion of general purpose technologies

Partners (10)

Lead Partner: Université de Lille

Department: College of Pharmacy

Address: 3, rue du Professeur Laguesse, 59006 Lille, France

Legal status: public

Total budget: EUR 1 773 069.36

ERDF budget: EUR 1 063 841.62

Centre Hospitalier Régional Universitaire de Lille

Name: Centre Hospitalier Régional Universitaire de Lille

Department: Research and Innovation Department

Address: 2 avenu Oscar Lambret, 59000 Lille, France

Legal status: public

Total budget: EUR 15 690.77

ERDF budget: EUR 9 414.46

Société d'Accélération du Transfert de Technologie, Nord France, SATT-Nord

Name: Société d'Accélération du Transfert de Technologie, Nord France, SATT-Nord

Department: SATT-Nord

Address: 25 Avenue Charles St Venant, 59800 Lille, France

Legal status: private

Total budget: EUR 39 574.23

ERDF budget: EUR 23 744.54

Universiteit Leiden

Name: Universiteit Leiden

Department: Leiden Academic Centre for Drug Research (LACDR) –Division of BioTherapeutics

Address: Einsteinweg 55, 2333 CC Leiden, Netherlands

Legal status: public

Total budget: EUR 403 191.43

ERDF budget: EUR 241 914.87

ProDigest

Name: ProDigest

Department: R&D

Address: Technologiepark 82, 9052 Zwijnaarde, Belgium

Legal status: private

Total budget: EUR 418 738.29

ERDF budget: EUR 251 242.97

University College London

Name: University College London

Department: School of Pharmacy

Address: 2939 Brunswick Square, WC1N 1AX London, United Kingdom

Legal status: public

Total budget: EUR 444 845.45

ERDF budget: EUR 266 907.28

Lattice Medical

Name: Lattice Medical

Department: R&D

Address: 80 rue du Docteur Yersin, 59120 LOOS, France

Legal status: private

Total budget: EUR 392 641.13

ERDF budget: EUR 235 584.67

Technische Universiteit Delft (TUD)

Name: Technische Universiteit Delft (TUD)

Department: BioMechanical Engineering Department /Biomaterials & Tissue Biomechanics

Address: Mekelweg 2, 2628 CD Delft, Netherlands

Legal status: public

Total budget: EUR 903 013.62

ERDF budget: EUR 541 808.17

Universiteit Gent

Name: Universiteit Gent

Department: Laboratory of Pharmaceutical Technology

Address: Ottergemsesteenweg 46, 9000 Gent, Belgium

Legal status: public

Total budget: EUR 304 705.00

ERDF budget: EUR 182 823.01

University of Cambridge

Name: University of Cambridge

Department: Department of Chemical Engineering and Biotechnology

Address: West Cambridge Site, CB3 0AS Cambridge, United Kingdom

Legal status: public

Total budget: EUR 441 208.90

ERDF budget: EUR 264 725.33

Partners map

Lead partner

Project partner

Summary

Project name (EN): Site-Specific Drug Delivery

Project acronym: Site Drug

Project start date: 2020-01-01

Project end date: 2023-03-31

Project status: closed

Total budget/expenditure: EUR 5 136 678.18

Total EU funding (amount): EUR 3 082 006.92

Total EU funding (co-financing rate): 0.60%

Co-financing sources:

Information regarding the data in keep.eu on the programme financing this project

Financing programme

2014 - 2020 INTERREG V-A France - Belgium - The Netherlands - United Kingdom (Les Deux Mers / Two seas / Twee Zeeën)

Last month that data in keep.eu was retrieved from the Programme's website or received from the Programme

2024-12-17

No. of projects in keep.eu / Total no. of projects (% of projects in keep.eu)

82 / 82 (100%)

No. of project partnerships in keep.eu / Total no. of project partnerships (% of project partnerships in keep.eu)

886 / 886 (100%)

Notes on the data

Information provided by the Programme in 2024-12.

Languages

Contact Form

Site-Specific Drug Delivery

Description

Thematic information

Partners (10)

Partners map

Summary

Information regarding the data in keep.eu on the programme financing this project

Disclaimer